The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a manuscript titled, “Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee”.
The development of clinical trials/demonstration projects in resource-limited settings, such as Sub-Saharan Africa, will play a critical role in providing equitable treatment options and advancing the field of IO, but knowledge on how to successfully design and execute these trials remains a barrier to expansion. To address this significant hurdle in the field, the Society for Immunotherapy of Cancer (SITC) convened the SITC Global Access and Impact Committee, as well as additional international stakeholders and experts in the field, to explore how analyzing unique populations, environmental factors, different co-morbidities, and efficacy considerations can serve stakeholders beyond LMICs to enrich global knowledge on the strategies that can be implemented to improve the application and future development of cancer immunotherapy. The group, including representatives from academia and industry from around the globe, provided expertise relevant to the successful implementation of clinical trials in LMICs and described how these trials can positively impact the entire IO community.